CN101522670B - 作为免疫调制剂的吡啶-3-基衍生物 - Google Patents

作为免疫调制剂的吡啶-3-基衍生物 Download PDF

Info

Publication number: CN101522670B
Authority: CN; China
Prior art keywords: methyl; hydroxyl; ethyl; pyridin; oxadiazoles
Prior art date: 2006-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN2007800333351A

Other languages

English (en)

Chinese (zh)

Other versions

CN101522670A (zh

Inventor

马丁·博利

大卫·莱曼

博里斯·马蒂斯

克劳斯·米勒

奥利弗·内勒

比特·斯蒂内

约尔格·韦尔克

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Actelion Pharmaceuticals Ltd

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-08

Filing date

2007-09-06

Publication date

2012-05-23

2007-09-06 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2009-09-02 Publication of CN101522670A publication Critical patent/CN101522670A/zh

2012-05-23 Application granted granted Critical

2012-05-23 Publication of CN101522670B publication Critical patent/CN101522670B/zh

Status Expired - Fee Related legal-status Critical Current

2027-09-06 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN2007800333351A 2006-09-08 2007-09-06 作为免疫调制剂的吡啶-3-基衍生物 Expired - Fee Related CN101522670B (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IB2006053187		2006-09-08
WOPCT/IB2006/053187		2006-09-08
IBPCT/IB2006/053187		2006-09-08
PCT/IB2007/053593 WO2008029370A1 (en)	2006-09-08	2007-09-06	Pyridin-3-yl derivatives as immunomodulating agents

Publications (2)

Publication Number	Publication Date
CN101522670A CN101522670A (zh)	2009-09-02
CN101522670B true CN101522670B (zh)	2012-05-23

Family

ID=38982768

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2007800333351A Expired - Fee Related CN101522670B (zh)	2006-09-08	2007-09-06	作为免疫调制剂的吡啶-3-基衍生物

Country Status (27)

Country	Link
US (1)	US8288554B2 (es)
EP (1)	EP2069335B1 (es)
JP (1)	JP5253400B2 (es)
KR (1)	KR101454937B1 (es)
CN (1)	CN101522670B (es)
AR (1)	AR062684A1 (es)
AU (1)	AU2007292992B2 (es)
BR (1)	BRPI0716633A2 (es)
CA (1)	CA2661315C (es)
CL (1)	CL2007002594A1 (es)
CY (1)	CY1113858T1 (es)
DK (1)	DK2069335T3 (es)
ES (1)	ES2400163T3 (es)
HK (1)	HK1135976A1 (es)
HR (1)	HRP20130180T1 (es)
IL (1)	IL197394A (es)
MA (1)	MA30717B1 (es)
MX (1)	MX2009002234A (es)
MY (1)	MY150661A (es)
NO (1)	NO20091409L (es)
NZ (1)	NZ576059A (es)
PL (1)	PL2069335T3 (es)
PT (1)	PT2069335E (es)
RU (1)	RU2454413C2 (es)
SI (1)	SI2069335T1 (es)
TW (1)	TWI399371B (es)
WO (1)	WO2008029370A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149853A (en) *	2006-09-07	2013-10-31	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives as immunomodulating agents
WO2008029370A1 (en)	2006-09-08	2008-03-13	Actelion Pharmaceuticals Ltd	Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) *	2006-09-21	2008-03-27	Actelion Pharmaceuticals Ltd	Phenyl derivatives and their use as immunomodulators
RU2009127095A (ru) *	2006-12-15	2011-01-20	Эбботт Лэборетриз (Us)	Новые оксадиазольные соединения
EP2125797B1 (en) *	2007-03-16	2014-01-15	Actelion Pharmaceuticals Ltd.	Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
RU2492168C2 (ru) *	2007-08-17	2013-09-10	Актелион Фармасьютиклз Лтд	Производные пиридина в качестве модуляторов s1p1/edg1 рецептора
AR069146A1 (es) *	2007-11-01	2009-12-30	Actelion Pharmaceuticals Ltd	Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
WO2009109906A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridine compounds
BRPI0910288A2 (pt) *	2008-03-07	2019-09-24	Actelion Pharmaceuticals Ltd	composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
EP2252609B1 (en) *	2008-03-07	2013-04-17	Actelion Pharmaceuticals Ltd.	Pyridin-2-yl derivatives as immunomodulating agents
KR20100134032A (ko)	2008-03-17	2010-12-22	액테리온 파마슈티칼 리미티드	선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
EP2177521A1 (en) *	2008-10-14	2010-04-21	Almirall, S.A.	New 2-Amidothiadiazole Derivatives
DE102008063561A1 (de)	2008-12-18	2010-08-19	Bayer Cropscience Ag	Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
EP2403849B1 (en) *	2009-03-03	2014-07-16	Merck Serono S.A.	Oxazole pyridine derivatives useful as S1P1 receptor agonists
DE102009002514A1 (de) *	2009-04-21	2010-10-28	Evonik Degussa Gmbh	Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
KR101923354B1 (ko) *	2009-05-04	2018-11-28	프로메틱 파마 에스엠티 리미티드	치환된 방향족 화합물 및 그의 약학적 용도
TW201107302A (en) *	2009-06-26	2011-03-01	Glaxo Group Ltd	Compounds
GB0911130D0 (en) *	2009-06-26	2009-08-12	Glaxo Group Ltd	Novel compounds
AR077413A1 (es)	2009-07-16	2011-08-24	Actelion Pharmaceuticals Ltd	Derivados piridin-4-ilo
US8399451B2 (en) *	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
US9216972B2 (en)	2009-10-29	2015-12-22	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
TW201120016A (en) *	2009-12-08	2011-06-16	Abbott Lab	Novel oxadiazole compounds
US8835470B2 (en)	2010-04-23	2014-09-16	Bristol-Myers Squibb Company	Mandelamide heterocyclic compounds
CN103124727B (zh)	2010-07-20	2015-03-25	百时美施贵宝公司	取代的3-苯基-1,2,4-噁二唑化合物
EP2619190B1 (en)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en)	2010-11-03	2012-05-10	Bristol-Myers Squibb Company	Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
PL2665720T3 (pl)	2011-01-19	2015-11-30	Idorsia Pharmaceuticals Ltd	Pochodne 2-metoksypirydyn-4-ylowe
KR101731739B1 (ko)	2012-08-17	2017-05-11	액테리온 파마슈티칼 리미티드	(2ｚ,5ｚ)-5-(3-클로로-4-((ｒ)-2,3-디하이드록시프로폭시)벤질리덴)-2-(프로필이미노)-3-(ｏ-톨릴)티아졸리딘-4-온의 제조 방법 및 그 방법에 사용되는 중간체
US9000016B2 (en) *	2012-11-05	2015-04-07	Allergan, Inc.	1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
UY35338A (es)	2013-02-21	2014-08-29	Bristol Myers Squibb Company Una Corporación Del Estado De Delaware	Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
MX363545B (es) *	2013-03-15	2019-03-27	Idorsia Pharmaceuticals Ltd	Derivados piridin-4-ilo.
EP2988744A4 (en) *	2013-04-26	2016-11-02	Merck Sharp & Dohme	THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR
WO2015073140A1 (en) *	2013-11-14	2015-05-21	Allergan, Inc.	1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
WO2015095444A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en)	2013-12-20	2017-11-21	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en)	2013-12-20	2017-10-10	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015108577A1 (en) *	2014-01-15	2015-07-23	Allergan, Inc.	Diphenyl urea derivatives as formyl peptide receptor modulators
WO2015138273A1 (en)	2014-03-13	2015-09-17	Merck Sharp & Dohme Corp.	2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
TWI689487B (zh)	2014-08-20	2020-04-01	美商必治妥美雅史谷比公司	經取代雙環化合物
JP6674967B2 (ja)	2015-05-20	2020-04-01	イドーシアファーマシューティカルズリミテッドＩｄｏｒｓｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	化合物（ｓ）−３−｛４−［５−（２−シクロペンチル−６−メトキシ−ピリジン−４−イル）−［１，２，４］オキサジアゾール−３−イル］−２−エチル−６−メチル−フェノキシ｝−プロパン−１，２−ジオールの結晶形
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
KR102482825B1 (ko)	2016-09-02	2022-12-29	브리스톨-마이어스 스큅 컴퍼니	치환된 트리시클릭 헤테로시클릭 화합물
US11059784B2 (en)	2017-08-09	2021-07-13	Bristol-Myers Squibb Company	Oxime ether compounds
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
KR20230154194A (ko) *	2021-02-10	2023-11-07	이칸 스쿨 오브 메디슨 엣 마운트 시나이	신장 섬유증의 치료를 위한 HIPK2의 옥사디아졸릴 디하이드로피라노[2,3-b]피리딘 억제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004056789A1 (en) *	2002-12-20	2004-07-08	Warner-Lambert Company Llc	Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005058848A1 (en) *	2003-12-17	2005-06-30	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3647809A (en) *	1968-04-26	1972-03-07	Chinoin Gyogyszer Es Vegyeszet	Certain pyridyl-1 2 4-oxadiazole derivatives
WO1991015583A1 (en)	1990-04-05	1991-10-17	The American National Red Cross	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
ZA917371B (en)	1990-09-20	1992-06-24	Merrell Dow Pharma	Calcium uptake inhibitors
DE4429465A1 (de) *	1994-08-19	1996-02-22	Bayer Ag	Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
DE19540027A1 (de) *	1995-10-27	1997-04-30	Gruenenthal Gmbh	Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US6423508B1 (en)	1998-03-09	2002-07-23	Smithkline Beecham Corporation	Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CN1313465C (zh)	1999-08-19	2007-05-02	Nps药物有限公司	杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
CN1853630A (zh)	2001-02-21	2006-11-01	Nps制药公司	杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
EP1470137B1 (en)	2002-01-18	2009-09-02	Merck & Co., Inc.	Edg receptor agonists
JP4709488B2 (ja)	2002-01-18	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
JP2005533058A (ja)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
DE10237883A1 (de) *	2002-08-19	2004-03-04	Merckle Gmbh Chem.-Pharm. Fabrik	Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003279915A1 (en)	2002-10-15	2004-05-04	Merck And Co., Inc.	Process for making azetidine-3-carboxylic acid
WO2004103279A2 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
CA2539438A1 (en)	2003-10-01	2005-04-14	Merck And Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
AU2005247110B2 (en)	2004-05-29	2010-08-26	7Tm Pharma A/S	CRTH2 receptor ligands for medicinal uses
WO2006010379A1 (en) *	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
WO2006047195A2 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
WO2006064757A1 (ja) *	2004-12-13	2006-06-22	Ono Pharmaceutical Co., Ltd.	アミノカルボン酸誘導体およびその医薬用途
US7846964B2 (en) *	2005-03-23	2010-12-07	Actelion Pharmaceuticals Ltd.	Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists
ES2365747T3 (es)	2005-03-23	2011-10-10	Actelion Pharmaceuticals Ltd.	Derivados de benzo[c]tiofeno hidrogenados como inmunomoduladores.
MX2007011672A (es)	2005-03-23	2007-11-15	Actelion Pharmaceuticals Ltd	Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1.
BRPI0609994A2 (pt)	2005-04-22	2011-10-18	Daiichi Sankyo Co Ltd	composto, composição medicinal e uso de um ou mais compostos ou um sal farmacologicamente aceitável dos mesmos 31/12 a61p 33/02 a61p 35/00 a61p 35/02 a61p 37/02 a61p 37/06 a61p 37/08
KR20080000622A (ko)	2005-04-26	2008-01-02	뉴로서치 에이/에스	신규한 옥사디아졸 유도체 및 이의 의학적 용도
MX2007015422A (es) *	2005-06-08	2008-02-21	Novartis Ag	Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p.
WO2006135694A2 (en) *	2005-06-10	2006-12-21	Acadia Pharmaceuticals Inc.	Uii-modulating compounds and their use
WO2006137019A1 (en) *	2005-06-24	2006-12-28	Actelion Pharmaceuticals Ltd	Novel thiophene derivatives
CN101203220A (zh)	2005-06-28	2008-06-18	阿斯利康(瑞典)有限公司	新用途
AR057894A1 (es) *	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
EP1979345B1 (en) *	2006-01-24	2009-11-04	Actelion Pharmaceuticals Ltd.	Novel pyridine derivatives
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
RU2008137553A (ru)	2006-02-21	2010-03-27	Юниверсити Оф Вирджиния Пэтент Фаундейшн (Us)	Фенил-циклоалкильные соединения, содержащие гетероциклические структуры
MX2008013990A (es) *	2006-05-09	2009-01-29	Pfizer Prod Inc	Derivados de cicloalquilamino acidos.
AR061841A1 (es) *	2006-09-07	2008-09-24	Actelion Pharmaceuticals Ltd	Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
MY149853A (en) *	2006-09-07	2013-10-31	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives as immunomodulating agents
WO2008029370A1 (en)	2006-09-08	2008-03-13	Actelion Pharmaceuticals Ltd	Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) *	2006-09-21	2008-03-27	Actelion Pharmaceuticals Ltd	Phenyl derivatives and their use as immunomodulators
KR20090057070A (ko)	2006-09-29	2009-06-03	노파르티스 아게	소염성 및 면역억제성을 갖는 옥사디아졸 유도체
UA91793C2 (ru) *	2006-10-07	2010-08-25	Смс Зимаг Акциенгезелльшафт	Способ эксплуатации конвертера
JP2008120794A (ja)	2006-10-16	2008-05-29	Daiichi Sankyo Co Ltd	ヘテロ環化合物を含有する医薬組成物
US20080138955A1 (en) *	2006-12-12	2008-06-12	Zhiyuan Ye	Formation of epitaxial layer containing silicon
RU2009127095A (ru)	2006-12-15	2011-01-20	Эбботт Лэборетриз (Us)	Новые оксадиазольные соединения
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
EP2125797B1 (en) *	2007-03-16	2014-01-15	Actelion Pharmaceuticals Ltd.	Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
RU2492168C2 (ru)	2007-08-17	2013-09-10	Актелион Фармасьютиклз Лтд	Производные пиридина в качестве модуляторов s1p1/edg1 рецептора
AR069146A1 (es)	2007-11-01	2009-12-30	Actelion Pharmaceuticals Ltd	Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
JP5503551B2 (ja) *	2007-12-10	2014-05-28	アクテリオンファーマシューティカルズリミテッド	新規なチオフェン誘導体
WO2009109906A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Pyridine compounds
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
EP2252609B1 (en) *	2008-03-07	2013-04-17	Actelion Pharmaceuticals Ltd.	Pyridin-2-yl derivatives as immunomodulating agents
BRPI0910288A2 (pt) *	2008-03-07	2019-09-24	Actelion Pharmaceuticals Ltd	composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.

2007
- 2007-09-06 WO PCT/IB2007/053593 patent/WO2008029370A1/en active Application Filing
- 2007-09-06 JP JP2009527263A patent/JP5253400B2/ja not_active Expired - Fee Related
- 2007-09-06 DK DK07826286.2T patent/DK2069335T3/da active
- 2007-09-06 MY MYPI20090939 patent/MY150661A/en unknown
- 2007-09-06 US US12/310,763 patent/US8288554B2/en not_active Expired - Fee Related
- 2007-09-06 PT PT78262862T patent/PT2069335E/pt unknown
- 2007-09-06 ES ES07826286T patent/ES2400163T3/es active Active
- 2007-09-06 AU AU2007292992A patent/AU2007292992B2/en not_active Ceased
- 2007-09-06 SI SI200731184T patent/SI2069335T1/sl unknown
- 2007-09-06 RU RU2009112726/04A patent/RU2454413C2/ru not_active IP Right Cessation
- 2007-09-06 KR KR1020097006863A patent/KR101454937B1/ko not_active IP Right Cessation
- 2007-09-06 BR BRPI0716633-8A2A patent/BRPI0716633A2/pt not_active IP Right Cessation
- 2007-09-06 CA CA2661315A patent/CA2661315C/en not_active Expired - Fee Related
- 2007-09-06 MX MX2009002234A patent/MX2009002234A/es active IP Right Grant
- 2007-09-06 NZ NZ576059A patent/NZ576059A/en not_active IP Right Cessation
- 2007-09-06 CL CL200702594A patent/CL2007002594A1/es unknown
- 2007-09-06 PL PL07826286T patent/PL2069335T3/pl unknown
- 2007-09-06 CN CN2007800333351A patent/CN101522670B/zh not_active Expired - Fee Related
- 2007-09-06 AR ARP070103941A patent/AR062684A1/es unknown
- 2007-09-06 EP EP07826286A patent/EP2069335B1/en active Active
- 2007-09-07 TW TW096133600A patent/TWI399371B/zh not_active IP Right Cessation
2009
- 2009-03-04 IL IL197394A patent/IL197394A/en not_active IP Right Cessation
- 2009-03-18 MA MA31728A patent/MA30717B1/fr unknown
- 2009-04-07 NO NO20091409A patent/NO20091409L/no not_active Application Discontinuation
2010
- 2010-03-02 HK HK10102256.3A patent/HK1135976A1/xx not_active IP Right Cessation
2013
- 2013-03-04 HR HRP20130180TT patent/HRP20130180T1/hr unknown
- 2013-03-26 CY CY20131100255T patent/CY1113858T1/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004056789A1 (en) *	2002-12-20	2004-07-08	Warner-Lambert Company Llc	Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates
WO2005058848A1 (en) *	2003-12-17	2005-06-30	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Also Published As

Publication number	Publication date
RU2454413C2 (ru)	2012-06-27
US8288554B2 (en)	2012-10-16
MX2009002234A (es)	2009-03-16
CN101522670A (zh)	2009-09-02
SI2069335T1 (sl)	2013-04-30
JP5253400B2 (ja)	2013-07-31
HK1135976A1 (en)	2010-06-18
AR062684A1 (es)	2008-11-26
CL2007002594A1 (es)	2008-06-06
NZ576059A (en)	2012-03-30
CY1113858T1 (el)	2016-07-27
EP2069335B1 (en)	2012-12-26
HRP20130180T1 (hr)	2013-03-31
IL197394A (en)	2013-08-29
ES2400163T3 (es)	2013-04-08
NO20091409L (no)	2009-04-07
KR20090060327A (ko)	2009-06-11
EP2069335A1 (en)	2009-06-17
TWI399371B (zh)	2013-06-21
AU2007292992A1 (en)	2008-03-13
AU2007292992B2 (en)	2013-01-10
KR101454937B1 (ko)	2014-10-27
RU2009112726A (ru)	2010-10-20
CA2661315A1 (en)	2008-03-13
PT2069335E (pt)	2013-03-04
MA30717B1 (fr)	2009-09-01
MY150661A (en)	2014-02-14
BRPI0716633A2 (pt)	2013-09-24
DK2069335T3 (da)	2013-02-18
PL2069335T3 (pl)	2013-05-31
US20100168005A1 (en)	2010-07-01
JP2010502694A (ja)	2010-01-28
CA2661315C (en)	2015-11-24
TW200817358A (en)	2008-04-16
IL197394A0 (en)	2009-12-24
WO2008029370A1 (en)	2008-03-13

Publication	Publication Date	Title
CN101522670B (zh)	2012-05-23	作为免疫调制剂的吡啶-3-基衍生物
CN101511827B (zh)	2012-02-01	作为免疫调制剂的吡啶-4-基衍生物
CN101627034B (zh)	2013-05-15	氨基-吡啶衍生物作为s1p1/edg1受体激动剂
CN101970430B (zh)	2013-05-08	嘧啶衍生物
CN101370496B (zh)	2012-07-04	作为s1p1/edg1受体促效剂的新型噻吩衍生物
CN101522645B (zh)	2013-01-09	苯衍生物及其免疫调节剂的用途
CN101528726B (zh)	2012-11-14	用作s1p1/edg1受体激动剂的噻吩衍生物
ES2389042T3 (es)	2012-10-22	Compuestos de piridina
ES2414533T3 (es)	2013-07-19	Derivados Piridin-2-ilo como agentes inmunomoduladores
WO2004110442A1 (en)	2004-12-23	Pyridine n-oxides as antiviral agents

Legal Events

Date	Code	Title	Description
2009-09-02	C06	Publication
2009-09-02	PB01	Publication
2009-10-28	C10	Entry into substantive examination
2009-10-28	SE01	Entry into force of request for substantive examination
2010-06-18	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1135976 Country of ref document: HK
2012-05-23	C14	Grant of patent or utility model
2012-05-23	GR01	Patent grant
2013-02-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1135976 Country of ref document: HK
2018-08-28	CF01	Termination of patent right due to non-payment of annual fee
2018-08-28	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20120523 Termination date: 20170906